Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
68Ga-EVG321
- Development stage
- Phase 2
- Lead developer
- Evergreen Theragnostics
- Modality
- Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptides
- Administration
- Intravenous
01
Overview
68Ga-EVG321 is a peptide-based radioligand diagnostic agent designed for positron emission tomography (PET) imaging. It targets the cholecystokinin-2 receptor (CCK2R), which is highly expressed in small cell lung cancer (SCLC) and potentially other tumors. The molecule consists of a Gallium-68 radioisotope chelated to a CCK2R-targeting peptide, enabling non-invasive whole-body quantification of tumor CCK2R expression. This allows for improved diagnosis, staging, and patient selection for subsequent radioligand therapy with its therapeutic pair, 177Lu-EVG321. The drug is being developed by Evergreen Theragnostics and originated from the Medical University of Innsbruck[1][3][6]. Its primary indication is as an imaging agent in SCLC to identify patients who may benefit from targeted radioligand therapies[1][5][6].
- Other names
- Gallium-68 EVG321Gallium68 EVG321Gallium 68 EVG321
02
Targets
CCK2R (Cholecystokinin 2 Receptor)
Beyond the preview
Go deeper on 68Ga-EVG321.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 68Ga-EVG321.